Richard Aranda
Chief Tech/Sci/R&D Officer bei GOSSAMER BIO, INC.
Vermögen: 234 583 $ am 31.03.2024
Profil
Richard Aranda is currently the Chief Medical Officer at Gossamer Bio, Inc. He previously worked as the Vice President-Clinical Development at Receptos LLC from 2015 to 2018, the Vice President-Medical Science & Inflammation at Novo-Nordisk Biochem, Inc. from 2011 to 2015, and as a Principal at Bristol Myers Squibb Co. from 2001 to 2011.
Dr. Aranda obtained his undergraduate degree from the University of California, Santa Cruz and holds doctorate degrees from Stanford University School of Medicine and Stanford School of Medicine.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
GOSSAMER BIO, INC.
0,09% | 18.03.2024 | 198 799 ( 0,09% ) | 234 583 $ | 31.03.2024 |
Aktive Positionen von Richard Aranda
| Unternehmen | Position | Beginn |
|---|---|---|
| GOSSAMER BIO, INC. | Chief Tech/Sci/R&D Officer | 01.06.2021 |
Ehemalige bekannte Positionen von Richard Aranda
| Unternehmen | Position | Ende |
|---|---|---|
| RECEPTOS INC | Corporate Officer/Principal | 01.01.2018 |
| Novo-Nordisk Biochem, Inc. | Corporate Officer/Principal | 01.01.2015 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01.05.2011 |
Ausbildung von Richard Aranda
| University of California, Santa Cruz | Undergraduate Degree |
| Stanford School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| GOSSAMER BIO, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Receptos LLC
 Receptos LLC Pharmaceuticals: MajorHealth Technology Receptos LLC engages in the provision of developing and commercializing of therapeutic candidates for the treatment of immune and inflammatory diseases. It offers Ozanimod for relapsing multiple sclerosis, Ozanimod for inflammatory bowel disease and RPC4046 for eosinophilic esophagitis. The company was founded by Marcus F. Boehm, Robert J. Peach, William H. Rastetter, Hugh Rosen and Raymond C. Stevens on September 26, 2008 and is headquartered in San Diego, CA. | Health Technology |
| Novo-Nordisk Biochem, Inc. |
